Deciding to stop taking buprenorphine is a significant step and one that deserves to be taken seriously. For most people, buprenorphine was prescribed as part of a medication-assisted treatment (MAT) plan for opioid dependency disorder (OUD), and it may have initially helped stabilize their lives. If you are looking for a way forward, understanding what is happening in your body, and what your options actually are, is the right place to start.
What Is Buprenorphine?
Buprenorphine is a semi-synthetic partial opioid agonist, a prescription opioid prescribed under the brand name Subutex. Suboxone, Sublocade, Zubsolv, and Cassipa are all buprenorphine-based medications used in the treatment of OUD. Buprenorphine is FDA-approved for opioid dependency and chronic pain management. As a partial agonist at the mu-opioid receptor, it suppresses withdrawal symptoms and cravings without producing the full euphoria of drugs like heroin or oxycodone, a property that makes it useful in MAT programs. When used for pain management, physical dependency can develop even when it is taken exactly as prescribed. When it is used as MAT, it represents a transfer and continuation of opioid dependency through ongoing opioid receptor activation, which still must be addressed when the patient is ready to stop.
QUICK FACTS: BUPRENORPHINE
- Drug Type
- MAT Medication / Partial Opioid Agonist
- Withdrawal Onset
- 24-72 hours after last sublingual dose
- Withdrawal Peak
- Days 3-5 after last dose
- Withdrawal Duration
- Acute physical symptoms 6-14 days; psychological symptoms 2-4 weeks; PAWS weeks to months
Why Does Buprenorphine Withdrawal Happen?
Buprenorphine works by binding to the same opioid receptors that the body's own endorphins normally activate. Over time, the central nervous system (CNS) adjusts to the presence of buprenorphine by reducing its natural endorphin production and increasing the density of opioid receptors throughout the body. When buprenorphine is discontinued, the CNS is left in a state of imbalance: endorphin levels are suppressed, while opioid receptors have multiplied and been conditioned to expect external stimulation that is no longer arriving. This produces the characteristic symptoms of withdrawal.
Because buprenorphine has an unusually long half-life of 25 to 70 hours and clears slowly from opioid receptors, withdrawal onset is delayed compared to short-acting opioids, but the duration of acute symptoms is significantly prolonged. Several factors influence how severe this process becomes. The duration of use matters: the longer buprenorphine has been taken, the more the body adapts to rely on it. Dose level is equally important, as patients on long-term maintenance high doses tend to experience more extended and intense withdrawal. Liver function affects how efficiently the body processes and clears buprenorphine, directly influencing the timing and severity of withdrawal onset. Metabolic rate varies from person to person and shapes the overall withdrawal experience.
Buprenorphine Withdrawal Symptoms
Early Symptoms
- Muscle and joint pain
- Nausea, vomiting, and diarrhea
- Fever and sweating
- Insomnia
- Headache
- Runny nose and watery eyes (rhinorrhea and lacrimation)
- Dilated pupils (mydriasis)
- Abdominal cramping
- Lethargy and fatigue
- Anxiety
- Mood swings
- Irritability and agitation
- Difficulty concentrating
- Opioid cravings
Symptoms Peak
- Severe muscle and joint pain
- Intense nausea, vomiting, and diarrhea
- High fever and profuse sweating
- Severe insomnia
- Intense opioid cravings
- Acute anxiety
- Abdominal cramping
- Dilated pupils
- Emotional dysregulation and mood swings
Acute Symptoms Subsiding
- Residual body aches (may persist through day 10)
- Mild nausea
- Continued insomnia
- Depression (intensifying as physical symptoms fade)
- Persistent anxiety
- Agitation and irritability
- Difficulty concentrating
Post-Acute Withdrawal Syndrome (PAWS)
- Depression and anhedonia (emotional blunting and indifference)
- Severe and persistent opioid cravings
- Attention deficit and cognitive fog
- Mood instability and emotional swings
- Persistent lethargy and low energy
- Exacerbation of underlying anxiety and depression
Post-Acute Withdrawal Syndrome (PAWS) refers to a cluster of psychological and neurological symptoms that persist well beyond the acute withdrawal phase. In buprenorphine dependency, PAWS can last months after the last dose, driven by the body's slow recovery of natural endorphin production and receptor rebalancing. This phase carries the highest risk of relapse, not because of a lack of willpower, but because the underlying biological imbalance has not been resolved. A case report published in PubMed specifically documents PAWS following buprenorphine discontinuation for opioid dependency, though broader long-term PAWS data for buprenorphine specifically remains limited.
Buprenorphine Withdrawal Timeline
Due to buprenorphine's long half-life, symptoms do not begin immediately. Initial signs include anxiety, restlessness, fatigue, early muscle aches, runny nose, and watery eyes. Symptoms begin mild and escalate steadily. Onset may occur as early as 24 hours or as late as 72 hours, depending on dose and duration of use.
This is the most physically demanding phase. Severe muscle and joint pain, nausea, vomiting, diarrhea, abdominal cramping, high fever, profuse sweating, insomnia, dilated pupils, intense opioid cravings, acute anxiety, and emotional dysregulation all converge during this window.
Flu-like symptoms and body aches may persist through day 10. As physical symptoms begin to ease, psychological symptoms intensify: depression, anxiety, agitation, and cognitive difficulty become the dominant experience. Insomnia continues throughout this phase.
Physical symptoms are largely resolved, but persistent psychological symptoms - depression, severe cravings, attention deficit, emotional indifference, mood instability, and lethargy - can continue for weeks to months. This phase represents the highest relapse risk period and is driven by incomplete endorphin- opioid receptor restoration.
Common Approaches to Quitting Buprenorphine
When people decide to stop taking buprenorphine, several approaches are most commonly pursued. However, all of these common options focus on detoxification and symptom mitigation rather than resolution of the underlying issue.
Supervised Dose Tapering
Gradual reduction of buprenorphine dose under physician supervision is the most commonly used approach. The American Society of Addiction Medicine (ASAM) recommends individualized taper schedules based on dose, duration of treatment, and patient goals. The dose is reduced over time, with the goal of allowing the CNS more time to adjust to reduced opioid receptor stimulation.
Does not address the underlying dysregulation of the endorphin-opioid receptor system. Buprenorphine tapers have a high failure rate in self-administered settings; research indicates they are most effective when medication is fully controlled by a supervised treatment center rather than managed at home. A study published in PubMed Central found that 7-day and 28-day tapers produced similar withdrawal severity outcomes, suggesting that taper length alone does not determine success. Relapse is very common after completing a taper. According to Bentzley et al., return to opioid use exceeded 50% within one month after cessation, as the biological imbalance in the endorphin- opioid receptor system remains unresolved.
Abrupt Cessation (Cold Turkey)
Cold turkey is chosen for its accessibility, no taper schedule, no physician coordination, and no gradual process to manage. However, that's exactly what makes this approach dangerous. Because of buprenorphine's long half-life, withdrawal onset is delayed 24 to 72 hours, but symptoms can be prolonged and intense, particularly for patients on long-term maintenance doses.
Does not address the underlying dysregulation of the endorphin-opioid receptor system. Abrupt cessation is not recommended by ASAM or clinical guidelines and significantly intensifies withdrawal compared to tapering. Patients who relapse after cold turkey cessation face elevated overdose risk due to rapidly lost opioid tolerance.
Medication-Assisted Transition (MAT)
Some patients transition from buprenorphine to a different MAT opioid under clinical supervision, or use adjunct non-opioid medications, such as clonidine for anxiety and sweating, anti-nausea agents, and sleep aids, to manage symptoms during a taper. Transitioning does not resolve the problem; it simply means moving from a partial opioid agonist to a full opioid agonist with its own dependency and withdrawal profile.
Does not address the underlying dysregulation of the endorphin-opioid receptor system. The body cannot begin restoring endorphin production and atrophy of opioid receptors while MAT opioids occupy those receptors. Transitioning to methadone or Suboxone replaces one form of opioid dependency with another. Symptom-management medications address discomfort only – they do not restore opioid receptor function or accelerate natural endorphin production.
Inpatient Medical Detox
Supervised inpatient withdrawal management provides 24-hour monitoring, IV fluids for dehydration, symptom-management support, and a controlled environment that prevents self-dosing.
Does not address the underlying dysregulation of the endorphin-opioid receptor system. Inpatient detox addresses acute withdrawal only and does not treat the neurobiological cause of opioid dependency. Relapse rates after discharge are high; the New York State Department of Health explicitly states that medically supervised withdrawal without ongoing opioid agonist treatment is not adequate treatment for opioid dependency.
Why Traditional Approaches Don't Lead to Lasting Results
None of the standard approaches to quitting buprenorphine address what is actually driving withdrawal, cravings, and relapse: the dysregulation of the endorphin- opioid receptor system itself.
Passive Restoration: Cold Turkey, Tapering, and Inpatient Detox
Does not address the underlying dysregulation of the endorphin- opioid receptor system. Cold turkey, tapering, and inpatient detox all rely on the same mechanism: time. They ask the body to passively restore endorphin- opioid receptor equilibrium on its own, a process that takes months to years, carries a high relapse risk throughout, and leaves many patients enduring prolonged PAWS with no biological support. Buprenorphine's unusually long half-life and slow receptor clearance make this passive waiting period particularly difficult. A study comparing 7-day and 28-day tapers found no meaningful difference in withdrawal severity - underscoring that simply extending the taper timeline does not resolve the underlying receptor imbalance.
Substitution: Switching to Another Prescription Opioid
Does not address the underlying dysregulation of the endorphin- opioid receptor system. The body cannot begin to atrophy the overpopulated opioid receptors while MAT opioids occupy them. Transitioning from buprenorphine to methadone or another prescription opioid does not end dependency; it transfers it. The body remains dependent on external opioid stimulation, and the endorphin- opioid receptor system cannot begin genuine restoration while opioid receptors are continuously stimulated. Most patients on opioid substitution never successfully taper off, because the biological driver of dependency, the receptor imbalance, is never treated.
How ANR Treats Buprenorphine Dependency at the Source
ANR (Accelerated Neuro-Regulation) is the only treatment designed to address what none of the approaches above can: the underlying physiological dysregulation of the endorphin- opioid receptor system caused by buprenorphine use.
25,000+
Patients treated globally
9 out of 10
Patients remain opioid-free long term
ANR follows a structured four-stage framework: Preparation: Treatment begins right away, before hospitalization. The medical team conducts pre-admission clinical evaluations, assessing each patient's unique needs, and prepares them physically and mentally. Every treatment plan is individualized to the patient's specific medical background, drug use history, dose level, and any co-existing conditions. Regulation: The hospital procedure - the central phase of ANR Treatment. Under sedation, withdrawal is induced and managed while endorphin- opioid receptor modulation takes place. The patient does not consciously experience withdrawal. The therapeutic goal is endorphin- opioid receptor equilibrium: restoring the receptor system to the state it was in before opioid exposure altered it. Stabilization: Patients are seen in person for 3 post-discharge follow-up visits. Any temporary discomfort during this period is like bouncing back from surgery; discomfort is healing, not illness. This phase is active, not passive — the CNS is completing its restoration with full biological support in place. Optimization: Over the following 6 to 12 months, patients consolidate their recovery through nutrition, physical activity, intellectual stimulation, and a daily naltrexone protocol. Naltrexone is non-addictive, creates no dependency, and can be stopped at any time.
STAGE 1
Preparation
STAGE 2
Regulation
STAGE 3
Stabilization
STAGE 4
Optimization
Developed by Dr. Andre Waismann, Founder of ANR Clinic, ANR Treatment works by restoring the endorphin- opioid receptor system to its pre-dependency state, not by managing symptoms or substituting one opioid for another, but by directly modulating the receptor system back to biological equilibrium. The treatment has been administered to over 25,000 patients globally, and 9 out of 10 patients remain opioid-free long-term.
Traditional approaches discharge patients into the PAWS phase with no biological resolution in place. Weeks to months of depression, cognitive fog, emotional blunting, and relentless cravings are left to be managed entirely through time and willpower. ANR resolves PAWS during hospitalization and the stabilization phases. Because the endorphin- opioid receptor system has been restored, patients leave without needing to endure weeks of lingering neurological suffering that follow every other approach.
For buprenorphine patients specifically, many of whom have already been through the cycle of opioid dependency, MAT, and failed attempts to taper, ANR offers something no taper schedule or transition protocol can: an end to the biological condition itself.
Frequently Asked Questions About Quitting Buprenorphine
How long does buprenorphine withdrawal last?
Acute physical withdrawal from sublingual buprenorphine typically begins 24 to 72 hours after the last dose, peaks around days 3 to 5, and resolves over 6 to 14 days. Psychological symptoms, including depression, anxiety, and cravings, can persist for 2 to 4 weeks. Post-Acute Withdrawal Syndrome (PAWS), characterized by mood instability, cognitive fog, and persistent cravings, can last weeks to months beyond that.
Is it safe to stop buprenorphine without tapering?
Stopping buprenorphine abruptly is not recommended by clinical guidelines. Because buprenorphine has a long half-life, withdrawal onset is delayed, but symptoms can be prolonged and severe - particularly for patients on long-term maintenance doses. Abrupt cessation also significantly increases relapse risk, and relapse after a period of abstinence carries an elevated overdose risk due to reduced opioid tolerance.
How long does it take to taper off buprenorphine?
Buprenorphine taper duration varies significantly based on dose, duration of use, and individual response. Even with a carefully supervised taper, many patients find that withdrawal symptoms persist because the underlying endorphin- opioid receptor imbalance is not resolved by dose reduction alone. There is no taper length that guarantees a symptom-free transition.
Why is buprenorphine so hard to stop?
Buprenorphine is difficult to stop because it has one of the highest binding affinities of any opioid at the mu-opioid receptor, and it dissociates from those receptors very slowly. Long-term use suppresses the body's natural endorphin production and increases the density of opioid receptors throughout the body. When buprenorphine is removed, the system lacks the endorphins needed to maintain normal function, producing a prolonged and psychologically demanding withdrawal that does not resolve quickly on its own.
What is ANR Treatment for buprenorphine dependency?
ANR (Accelerated Neuro-Regulation) is a comprehensive medical treatment that restores the endorphin- opioid receptor system to its pre-dependency state. Unlike tapering or switching prescription opioids, ANR addresses the biological root of buprenorphine dependency directly, eliminating the driver of cravings and withdrawal rather than managing symptoms. It follows a four-stage framework – Preparation, Regulation, Stabilization, and Optimization - and has been completed by over 25,000 patients globally.
How much does ANR Treatment cost?
The cost of the ANR Treatment is $21,500. It is an elective medical procedure and is not covered by insurance. Financing options are available to help patients plan for treatment: https://anrclinic.com/financing/.
Related Articles
Sources / References
- Kumar, R., Viswanath, O., & Saadabadi, A. (2024). Buprenorphine. In StatPearls [Internet]. StatPearls Publishing. Last updated June 8, 2024. https://www.ncbi.nlm.nih.gov/books/NBK459126/
- Amass, L., Ling, W., Freese, T.E., et al. (2004). Bringing buprenorphine-naloxone detoxification to community treatment providers: the NIDA Clinical Trials Network field experience. American Journal on Addictions, 13(Suppl 1):S42-66. https://pmc.ncbi.nlm.nih.gov/articles/PMC1255908/
- Lofwall, M.R., & Walsh, S.L. (2014). Buprenorphine tapering schedule and illicit opioid use. PMC / PubMed Central, National Institutes of Health. https://pmc.ncbi.nlm.nih.gov/articles/PMC3150159/
- Post-acute Withdrawal Syndrome. PubMed, National Library of Medicine. https://pubmed.ncbi.nlm.nih.gov/36731102/
- Schiller, E.Y., Gokarakonda, S.B., & Attia, F.N. (2023). Opioid Withdrawal. In StatPearls [Internet]. StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK526012/
- Waismann, A., Kabemba, A., Medowska, O., Salzman, R., Philpott, C., & Patel, M.M. (2023). Hemodynamic and Pulmonary Safety Profile of the Accelerated Neuroregulation Procedure. NeuroRegulation, 10(4), 253-259. https://doi.org/10.15540/nr.10.4.253
- Buprenorphine Withdrawal Syndrome. PMC / PubMed Central, National Institutes of Health. https://pmc.ncbi.nlm.nih.gov/articles/PMC2970944/
- New York State Department of Health. Buprenorphine Module 3: Clinical Use of Buprenorphine for Opioid Use Disorder. https://health.ny.gov/publications/0112.pdf
- Bentzley et al. (2015). Discontinuation of buprenorphine maintenance therapy: perspectives and outcomes. PubMed, National Library of Medicine. https://pubmed.ncbi.nlm.nih.gov/25601365/